ArticleFrontiers in immunology2026
Integrating network pharmacology, molecular docking and experimental verification to explore the therapeutic effect of piceatannol on rheumatoid arthritis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Selected traditional Chinese herbal medicines for the treatment of atopic dermatitis - research progress on the effect and mechanism of actions.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Piceatannol (PIC) exhibits antioxidant and anti-inflammatory activities. This study integrates network pharmacology and experimental validation to investigate its potential role in rheumatoid arthritis (RA). Methods: PIC targets were predicted using public databases. RA-related differentially expressed genes (DEGs) were identified from Gene Expression Omnibus (GEO) datasets (|logFC| ≥ 1 and P-value < 0.05). Intersection genes were analyzed via protein-protein interaction (PPI) network (hub gene selection), molecular docking (binding affinity < -5.0 kcal/mol as threshold), ConnectivityMap and molecular dynamics simulation. Experimental validation included CCK8, flow cytometry, real-time quantitative PCR (RT-qPCR), Western blotting, and an adjuvant-induced arthritis (AIA) rat model. Results: 35 intersecting genes were identified, from which 6 hub genes (SYK, CXCL8, TNF, NFKB1, PPARG, and CASP8) were selected. PIC showed stable binding to all hub genes (affinities: -5.6 to -7.8 kcal/mol). ConnectivityMap suggested a regulatory relationship between PIC and SYK. Molecular dynamics simulations demonstrate that the PIC-SYK complex maintains stable structural integrity. Experimental validation showed that PIC reduced MH7A cell viability, induced G2/M arrest and apoptosis, and downregulated mRNA levels of SYK, NFKB1, and CASP8, consistent with predictions. Conclusion: These preliminary findings suggest that PIC exerts therapeutic effects in RA models, potentially via SYK/NFKB1/CASP8. The study provides a theoretical basis for further evaluation of PIC in RA, while acknowledging the exploratory nature of network pharmacology and preclinical models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.